With a $100 capital and a 6-month horizon, we’ve constructed a concentrated micro-cap portfolio aiming for maximum return. All picks are U.S.-listed micro-cap stocks (sub-$300M market caps) chosen for strong catalysts or growth potential by December 27, 2025.
We’ve balanced high-upside biotech plays with an AI/tech growth stock, and we’ll actively manage risk through position sizing and stop-loss orders.
- Abeona Therapeutics (ABEO) – 6 shares ≈ $36 (36% of portfolio)
- Candel Therapeutics (CADL) – 5 shares ≈ $28 (28% of portfolio)
- Cloudastructure Inc (CSAI) – 15 shares ≈ $30 (30% of portfolio)
- Cash Reserve: ≈ $6 (6% cash for flexibility or fees)
Each stock is a full-share position and was selected based on verifiable positive research and upcoming catalysts. Below we detail the thesis for each holding and our risk management plan.